Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

3.3K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
3.3K
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

6.5K
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
6.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Propranolol monotherapy versus propranolol plus prednisone for diffuse infantile hepatic haemangioma: a randomized clinical trial.

World journal of pediatrics : WJP·2026
Same author

Prevalence and Severity of Coronary Artery Calcification Assessed by Low-Dose Computed Tomography in Individuals With Type 2 Diabetes With and Without Diabetic Foot: A Cross-Sectional Study.

Journal of diabetes·2026
Same author

Hybrid Cardiac <sup>68</sup>Ga-FAPI-4 PET/MRI in Dilated Cardiomyopathy: A Feasibility and Pilot Study.

Radiology·2026
Same author

Impact of Systemic-to-Pulmonary Artery Shunt Embolization on Right Heart Hemodynamics in Patients with Bronchiectasis.

Journal of vascular and interventional radiology : JVIR·2026
Same author

Hydrophilicity engineering of amphiphilic macrocyclic MRI contrast agents for enhanced hepatic targeting efficiency.

Biomaterials·2026
Same author

Severity-dependent shift in knee osteoarthritis toward a dominant varus-flexion alignment phenotype on weight-bearing 3D imaging.

Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA·2026

Related Experiment Video

Updated: Dec 29, 2025

An In Vitro Model for Studying Cellular Transformation by Kaposi Sarcoma Herpesvirus
09:53

An In Vitro Model for Studying Cellular Transformation by Kaposi Sarcoma Herpesvirus

Published on: August 25, 2017

9.2K

Kaposiform hemangioendothelioma: current knowledge and future perspectives.

Yi Ji1, Siyuan Chen2, Kaiying Yang3

  • 1Division of Oncology, Department of Pediatric Surgery, West China Hospital of Sichuan University, Chengdu, 610041, China. jijiyuanyuan@163.com.

Orphanet Journal of Rare Diseases
|February 5, 2020
PubMed
Summary

Kaposiform hemangioendothelioma (KHE) is a rare vascular tumor. Sirolimus shows promise, but novel targeted treatments are needed for better outcomes in KHE patients.

Keywords:
AngiogenesisKaposiform hemangioendotheliomaKasabach-Merritt phenomenonLymphangiogenesisTreatment

More Related Videos

Laparoscopic Anatomical Right Hemihepatectomy via the In Situ Anterior Approach
05:30

Laparoscopic Anatomical Right Hemihepatectomy via the In Situ Anterior Approach

Published on: August 8, 2025

418
Identifying Dysregulated Genes Induced by Kaposi's Sarcoma-associated Herpesvirus KSHV
07:02

Identifying Dysregulated Genes Induced by Kaposi's Sarcoma-associated Herpesvirus KSHV

Published on: September 14, 2010

13.0K

Related Experiment Videos

Last Updated: Dec 29, 2025

An In Vitro Model for Studying Cellular Transformation by Kaposi Sarcoma Herpesvirus
09:53

An In Vitro Model for Studying Cellular Transformation by Kaposi Sarcoma Herpesvirus

Published on: August 25, 2017

9.2K
Laparoscopic Anatomical Right Hemihepatectomy via the In Situ Anterior Approach
05:30

Laparoscopic Anatomical Right Hemihepatectomy via the In Situ Anterior Approach

Published on: August 8, 2025

418
Identifying Dysregulated Genes Induced by Kaposi's Sarcoma-associated Herpesvirus KSHV
07:02

Identifying Dysregulated Genes Induced by Kaposi's Sarcoma-associated Herpesvirus KSHV

Published on: September 14, 2010

13.0K

Area of Science:

  • Vascular Oncology
  • Pediatric Oncology
  • Rare Diseases

Background:

  • Kaposiform hemangioendothelioma (KHE) is a rare vascular neoplasm characterized by abnormal angiogenesis and lymphangiogenesis.
  • KHE presents with significant morbidity and mortality, often complicated by Kasabach-Merritt phenomenon (KMP), a life-threatening coagulopathy.
  • Current management of KHE is challenging due to its heterogeneity and associated comorbidities, with no FDA-approved therapies.

Purpose of the Study:

  • To review the current understanding of Kaposiform hemangioendothelioma (KHE).
  • To summarize the epidemiology, etiology, pathophysiology, clinical features, diagnosis, and treatment of KHE.
  • To discuss recent advancements and future perspectives in KHE management.

Main Methods:

  • Comprehensive literature review of KHE.
  • Analysis of epidemiological, etiological, and pathophysiological data.
  • Evaluation of current and emerging treatment strategies, including sirolimus.

Main Results:

  • KHE pathogenesis remains largely undiscovered, highlighting a critical knowledge gap.
  • Sirolimus demonstrates satisfactory efficacy in treating KHE, offering a potential therapeutic option.
  • Existing treatments are varied, with ongoing clinical trials exploring new interventions.

Conclusions:

  • There is an urgent need for novel targeted therapies for KHE based on a deeper understanding of its pathogenesis.
  • Improving patient outcomes and quality of life requires advancements in KHE treatment strategies.
  • Continued research into KHE is essential for developing more effective and specific therapeutic approaches.